Table 1 Comparison of demographic, clinical and laboratory characteristics based on Lp-PLA2 tertiles

Male Gender (n, %)

109 (90)

114 (93)

113 (89)

0.43

Age (years)

63 ± 10

62 ± 12

61 ± 11

0.44

Body mass index (kg/m²)

28.04 ± .4

28.58 ± 3.79

28.02 ± 3.40

0.43

Diabetes mellitus (n, %)

39 (30)

31 (25)

29 (23)

0.28

Hypertension (n, %)

96 (78%)

92 (76)

99 (79)

0.88

Hyperlipidemia (n, %)

98 (80)

91 (75)

89 (73)

0.25

Smoking history (n, %)

100 (82)

102 (84)

102 (84)

0.91

 Current smokers (n, %)

29 (22)

24 (20)

34 (28)

 Former smokers (n, %)

71 (60)

78 (64)

68 (56)

Heart Failure (n, %)

20 (16)

26 (22)

22 (18)

0.57

Family History for CAD (n, %)

31 (25)

33 (26)

33 (26)

0.94

Previous myocardial infarction (n, %)

52 (43)

47 (39)

58 (46)

0.51

CAD Duration (months)

40 (26–55)

47 (32–61)

46 (24–62)

0.15

Statins (n, %)

110 (91)

101 (82)

105 (84)

0.19

β-blockers (n, %)

83 (68)

80 (66)

93 (74)

0.33

Antidiabetic agents (n, %)

32 (27)

30 (25)

26 (21)

0.25

ACEi or ARBs

81 (68)

75 (61)

77 (62)

0.51

Systolic arterial pressure (mm Hg)

126 ± 20

125 ± 15

128 ± 19

0.42

Diastolic arterial pressure (mm Hg)

77 ± 12

77 ± 10

78 ± 10

0.82

Serum glucose (mg/dL)

119 ± 44

116 ± 43

110 ± 40

0.30

Cholesterol (mg/dL)

156 ± 35^a

165 ± 40^a

171 ± 46^a

0.03

LDL (mg/dL)

93 ± 30^a

100 ± 32^a

104 ± 35^a

0.04

HDL (mg/dL)

40 ± 10

42 ± 11

41 ± 10

0.57

Triglycerides (mg/dL)

129 ± 54

141 ± 74

136 ± 74

0.42

Lp-PLA2 (μg/L)

75 (60–92)

120 (113–130)

160 (149–179)

< 0.001

EID (%)

14.62 ± 7.51

14.42 ± 5.17

14.05 ± 3.92

0.29

FMD (%)

5.20 ± 2.52

4.61 ± 1.97

4.43 ± 2.37

0.03

AIx (%)

22.36 ± 8.92^a

24.33 ± 9.65^a

24.65 ± 8.69^a

0.12